Advisor Group Holdings, Inc. Global Blood Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.4 - $68.18 $9,590 - $20,181	-296 Reduced 36.23%	521 $35,000
Q2 2022 Aug 10, 2022	SELL	$22.3 - $37.39 $12,822 - $21,499	-575 Reduced 41.31%	817 $27,000
Q1 2022 May 04, 2022	SELL	$25.68 - $35.59 $590 - $818	-23 Reduced 1.63%	1,392 $48,000
Q3 2021 Nov 05, 2021	SELL	$25.48 - $37.34 $57,304 - $83,977	-2,249 Reduced 61.38%	1,415 $36,000
Q2 2021 Aug 02, 2021	BUY	$32.46 - $43.42 $9,673 - $12,939	298 Added 8.85%	3,664 $128,000
Q1 2021 May 13, 2021	BUY	$38.94 - $50.85 $67,521 - $88,173	1,734 Added 106.25%	3,366 $137,000
Q4 2020 Feb 10, 2021	BUY	$37.65 - $63.77 $31,851 - $53,949	846 Added 107.63%	1,632 $71,000
Q3 2020 Nov 12, 2020	SELL	$52.76 - $74.49 $71,120 - $100,412	-1,348 Reduced 63.17%	786 $45,000
Q2 2020 Aug 14, 2020	SELL	$48.73 - $81.82 $242,675 - $407,463	-4,980 Reduced 70.0%	2,134 $136,000
Q1 2020 May 18, 2020	BUY	$41.72 - $87.2 $296,796 - $620,340	7,114 New	7,114 $154,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.